

***Together, we can do this***

# Strategies to Address British Columbia’s Prescription Opioid Crisis

*Recommendations from the British Columbia Node of the Canadian Research Initiative on Substance Misuse*

November 2015

***Together, we can do this***

Strategies to Address British Columbia’s Prescription Opioid Crisis

### Recommendations from the British Columbia Node of the Canadian Research Initiative on Substance Misuse

30

Executive summary

Recent events in British Columbia have highlighted the

urgency with which policy makers, regulatory bodies and 25

clinicians need to act together to address the public health harms related to pharmaceutical opioids and other addictive pharmaceutical drugs. This report briefly describes the provincial pharmaceutical opioid problem and provides

several key recommendations for immediate steps to reduce 20

fatal overdoses, misuse, addiction and other severe harms

related to unsafe opioid prescribing in BC.

### 15

*fig 1*

# Annual opioid dispensing (not including methadone)

in BC, 2005–2013 10

# Weak opioids

*DDD/1000 population/day*

### 5

Strong opioids

*Fischer et al., 2014.*

*\* DDD = defined daily dose*

0

2005 2009 2013

The prescription opioid epidemic

Canada has the second highest opioid consumption rate among de veloped countries, with the rate of pharmaceutical opioid use tripling in Canada over the past decade.1-3 Despite similar rates of chronic pain across Canada, there is substantial variation in the rates and types of opioids prescribed across provinces.4-8 For example, British Columbia (BC) dispenses more than double the amount of opioids compared to Quebec, the lowest opioid dispensing

Coinciding with the dramatic increases in opioid prescribing in BC, there are high rates of opioid dependence, addiction and misuse that have contributed to significant health and social harms. In 2013, there were more than 330 deaths in BC related to illegal drug overdose including opioids. Of these deaths, 87% were accidental.19 Pharmaceutical opioids account for a large proportion of these deaths, to the extent that the number of pharmaceutical opioid-

province.6,8 Additionally, from 2005 to 2011, the rate of dispensing strong opioids in BC increased by almost 50% overall, including a 135% increase in oxycodone dispensation.6 Notably, these increases in opioid prescribing conflict with the increasing body of research suggesting that opioids may have limited long-term effectiveness for treating chronic non-cancer pain, and that the risk profile of opioids may outweigh their potential short- term benefits in cases of mild to moderate acute pain.9-11

In addition to an increased rate of opioid prescribing, there is evidence of inappropriate and high-risk opioid prescribing practices

related deaths exceeds the number of deaths from motor vehicle accidents involving alcohol in BC (Figure 2).13,19–21 Furthermore, among the pharmaceutical opioid- related deaths in BC, 93% involved at least one other high-risk medication (e.g., benzodiazepines).21 Although rates of prescription opioid- related death in BC have plateaued in recent years, the province is still experiencing annual mortality rates of

*fig 2*

**5**

*deaths per 100,000 people per year in BC*

#### Pharmaceutical opioids

**4**

**3**

**2**

#### 1 Alcohol/drug-related motor vehicle accidents

**0**

in BC. For instance, while patients on methadone commonly have chronic pain,

close to 4 deaths per 100,000

people.13

2009 2010 2011 2012

*Year*

2013

past research suggests that 35% of patients on methadone maintenance treatment in BC are co-prescribed opioids that are often not prescribed by the patient’s primary methadone provider.12 This is problematic

Studies ha ve sug gested that approximately 40% of prescribed pharmaceutical opioid-related deaths occur among people who are

More people die in BC each year from pharmaceutical opioids (including methadone) than from alcohol/drug- related motor vehicle accidents.13,19–21

since co-prescriptions with methadone have important safety considerations, as evidenced by a recent study of provincial mortality data found that methadone was involved in 25% of pharmaceutical opioid-related deaths in BC.13 Equally concerning are the persistently high rates of benzodiazepine prescribing in BC,14 given that co-prescription of benzodiazepines and opioids has long been known to be a major risk factor for fatal overdose.15-18

prescribed opioids above recommended safe-dosing guidelines.22 Furthermore, deaths related to prescribed pharmaceutical opioids correlate strongly with rates of opioid dispensation in BC.23 In addition to opioid overdose and mortality,24 there are extensive health and social harms associated with pharmaceutical opioids, including injuries and trauma;25 increased risk of costly emergency department visits;26,27 diversion to street-based markets, drug dealing and other

addiction-associated petty crime.3,28 Additionally concerning is evidence highlighting the growing number of infants being born with opioid addiction in Canada.29 Finally, recent evidence has demonstrated that many individuals who initially used pharmaceutical opioids or benzodiazepines illicitly may eventually transition to heroin or intravenous drug use thus substantially increasing the risk for blood-borne infections and overdose.30-36

In the face of this evidence, change has been slow to come. This brief paper was prepared through

the secretariat of the British Columbia node of the CIHR Canadian Research Initiative on Substance Misuse (CRISM). The development of this document included a range of expert stakeholders through the network’s membership and other experts (Appendix A). This urgent call to action outlines changes that can be immediately implemented in BC to substantially reduce the rates of overdose death, addiction and related harms that stem directly from the current system.

# Urgent need for action in British Columbia

While the pharmaceutical opioid epidemic has emerged throughout North America, recent events in BC have highlighted the urgency with which BC policy makers must act to address the public health harms related to pharmaceutical opioids and other addictive pharmaceutical drugs. Despite the scale of the present public health problem, strategies to meaningfully address unsafe prescribing have not been implemented. This is despite the fact that, ultimately, prescribers are largely responsible for the burgeoning illicit market in pharmaceutical opioids that has developed on the streets of BC.37-40 In fact, the entry of organized crime groups into the manufacturing of counterfeit pharmaceutical opioids (which often contain fentanyl) to fuel the street market for illicit or diverted opioids is arguably a direct result of longstanding unsafe physician prescribing practices.41-43

Specifically, BC has witnessed a spike in fentanyl related overdoses and deaths. Within only two years, there has been a seven-fold increase in fentanyl detected deaths in BC (from 13 deaths in 2012 to 90 deaths in 2014), representing 25% of all illicit drug related deaths in the province in 2014.44,45 In 2015, there have been several high profile deaths from fentanyl in BC,46-48 as well as 16 cases of suspected fentanyl overdoses in a single day in Vancouver.49-51 This worsening of the situation has occurred despite focused drug-law enforcement on the illicit fentanyl trade that has included at least 11 search warrants, 8 charges and 500,000 pills

seized in Metro Vancouver alone.41,52,53 Based on past evidence regarding the limited effectiveness of police seizures on controlling the availability of illicit drugs, it is unlikely that law enforcement efforts are a promising solution to this problem.54,55

## *In 2015, sixteen cases of suspected fentanyl overdoses were once reported in a single*

*day in Vancouver.*

Equally concerning are the persistently high prescribing rates of benzodiazepines in BC. Benzodiazepines are sedating hypnotic medications that, despite limited evidence of effectiveness and clear evidence of harms (e.g., addiction, fatal overdose, etc.), continue to be regularly used to treat sleep disorders and other minor health conditions for which there are much safer alternatives. In fact, benzodiazepines remain among the most commonly prescribed and misused types of psychoactive drug in the world, despite their link to serious harms, including cognitive impairment and decline (i.e., dementia), accidents and injuries, dependence and addiction, and fatal overdose — especially when used in combination with opioids or alcohol.56-58 Locally, recent research has found that benzodiazepine use

was associated with elevated rates of HIV infection among a cohort of people who inject drugs, and addiction to benzodiazepines is known to be extremely difficult to treat.59 In light of these risks, many clinical guidelines now recommend against prescribing benzodiazepines, yet inappropriate prescribing has continued to persist in BC.14 As a result, the percentage of pharmaceutical opioid related overdose deaths involving benzodiazepines in BC increased 600% between 2004 and 2013.13

# Areas for intervention

In the wake of the crisis that exists in BC, there has yet to be sufficient action from various colleges (i.e., College of Physicians and Surgeons of BC, College of Pharmacists of BC, College of Registered Nurses of BC, College of Dental Surgeons of BC, College of Veterinarians of BC) or other regulatory bodies across the province. This situation is likely a result of these groups waiting on Health Canada for action, coupled with the fact that no single group (e.g., regulatory bodies, police, etc.) has a clear mandate to address the current epidemic.

Fortunately, BC is uniquely positioned to rapidly implement several safeguards to reduce unsafe prescribing practices through the province’s PharmaNet system and other inter ventions. PharmaNet is an electronic information system that records data (e.g., drug name, dose, quantity, duration, prescribing practitioner, dispensing pharmacy) on all prescriptions dispensed at community pharmacies in BC.60 Previous research has suggested that the real-time, centralized nature of PharmaNet, which allows prescribers and pharmacists to access patients’ current prescription information, can be effective in reducing inappropriate prescriptions of opioids and benzodiazepines by approximately 30-50%.61 Notably, this study was performed at a time when only pharmacies had access to PharmaNet, suggesting that there is room for even greater reduction of inappropriate prescribing if PharmaNet is more widely utilized by prescribers and pharmacies. To this end, enabling physicians and nurse practitioners to access patients’ opioid

prescription history promotes optimal opioid prescribing practices.62

However, presentl y, physicians and nurse practitioners in BC are able — but not required — to use PharmaNet when prescribing medications. Here, it is estimated that less than 30% of physicians in BC have enrolled for PharmaNet,62 which means that over 70% of BC physicians may be writing opioid prescriptions without knowing if the patient in front of them is already prescribed opioids from multiple other practitioners. This is a very real concern, as evidenced by the case of one BC resident who received more than 23,000 pills of oxycodone from more than 50 physicians and 100 pharmacies over five years.64

## *Over 70% of BC physicians may be writing opioid*

*prescriptions without knowing if the patient in front of them is already prescribed opioids from multiple other practitioners.*

Additionally, practitioners who do not use PharmaNet may be unaware if a patient is receiving medications that pose high risk for overdose if co- prescribed with opioids, such as benzodiazepines or methadone. Furthermore, it is not currently required that benzodiazepines are prescribed on a duplicate prescription pad, which is an additional safeguard that is in place for opioids and other medications that pose high risk for misuse, diversion or overdose.65 Prescription monitoring for benzodiazepines has already been enacted in other settings including Alberta and New York.66,67 A study of the New York triplicate prescription program found that benzodiazepine prescribing was reduced by nearly 50% after the program’s implementation. These reductions were sustained for at least seven years after the program’s implementation, and most

patients did not require supplemental medication once their benzodiazepine prescriptions were discontinued.67

In addition to clinic-level prescribing practices, due to common pain and injury presentations, emergency departments can be another source of opioids. One study conducted at Vancouver General Hospital found that patients who were prescribed

received little training on how to safely prescribe opioids or how to identify and treat opioid addiction. In fact, only one third of Canadian universities provide mandatory instruction in pain management as part of undergraduate medical training. Not surprisingly, it has been estimated that only approximately 30% of Canadian family physicians feel strongly confident in their opioid

69,70

opioids upon discharge from the emergency

prescribing skills.

Furthermore, primary care

department had triple the odds of experiencing an adverse event within two weeks.68 Given the demands placed on emergency department staff for providing pain relief among injured and other patients who present to emergency rooms,

physicians have demonstrated high rates of

continuing ineffective opioid prescriptions, being unaware of opioid monitoring guidelines and demonstrating low levels of knowledge regarding safe opioid prescribing in the context of chronic

62

research and educational interventions tailored to

pain treatment.

Similarly, previous studies have

emergency department settings — such as clinical guidelines, electronic decision support tools, and

found that up to 94% of primary care physicians

may be unable to identify symptoms or methods of

71-73

clinician education — require resources to support

problematic substance use.

Recommendations

opportunities for safer opioid prescribing in this environment.

In the absence of the above safeguards, some limitations of Canadian prescribers should be noted. For instance, physicians in BC have traditionally

regarding the need for greater investment in

prescriber education (including nurse practitioners and other prescribers) in addiction and pain management, including the role of non-opioid analgesics for pain management, are described on the next page.

# Recommendations

In light of the evidence and the unique characteristics of the system of care in BC, a number of steps should immediately be taken to reduce the harms of the pharmaceutical opioid epidemic in British Columbia. These steps include:

#### StrategieS for improved preScribing practiceS

1. Make registration for PharmaNet free, and legally require all clinicians with prescribing authority to be registered for PharmaNet and routinely check patients’ PharmaNet profiles when writing prescriptions. Exemptions to this requirement could be provided for individuals who practice in areas without Internet access or with other barriers.
2. Revise duplicate prescription pads to include a checkbox indicating that the prescribing practitioner has fulfilled his or her legal responsibility to review a patient’s PharmaNet record, thereby ruling out duplicate or high-risk co-prescriptions.
3. Put in place enforcement measures to ensure that pharmacies are checking PharmaNet to confirm that duplicate prescriptions or other evidence of inappropriate medical care is further brought to the attention of prescribing practitioners and regulatory authorities.
4. Change requirements for benzodiazepine prescribing such that benzodiazepines require a prescription on a duplicate prescription pad, in the same way that opioid prescriptions must be written in BC.65,67
5. Implement a maximum upper dispense limit for the amount of opioids that a patient may be dispensed at any one time.

#### StrategieS to improve opioid addiction care

1. Dedicate investments into addiction treatment.

For instance, buprenorphine/naloxone—a proven treatment for opioid addiction—should be the first line pharmacotherapy option (along with methadone) for opioid addiction, given its superior safety profile with respect to overdose risk compared to methadone.74-77

1. Improve access to buprenorphine/naloxone by eliminating the requirement that prescribers must have methadone exemptions in order to prescribe buprenorphine/naloxone.

This requirement is unnecessar y given the low misuse potential of buprenorphine/naloxone and the low number of buprenorphine/naloxone prescribers the exemption requirement creates.78 In lieu of the methadone exemption, prescribers would be

required to complete an online training module on buprenorphine/naloxone prescribing.

1. Invest in recovery-oriented care for individuals with opioid addiction.
2. Consider comprehensive patient education with regards to risks of poly-substance use and overdose prevention, recognition and response including take home naloxone prescription.79,80
3. Increase prescribers’ capacity for opioid agonist treatments (e.g., methadone and buprenorphine/ naloxone) via novel collaborative strategies.

#### Long-term strategies to improve preScriber knowledge

1. Invest in BC’s medical curricula and continuing medical education for physicians, nurses and other clinicians in addiction diagnosis, treatment and recovery; pain management including

the use of non-opioid analgesics; and safe opioid prescribing, including the potential for serious adverse effects when opioids are co-prescribed with benzodiazepines and other psychotropic medications.38,81

1. Coinciding with benzodiazepines transitioning to a duplicate prescription requirement, investment should be made in education for BC prescribers on the known serious harms and clinical limitations of benzodiazepines, as well as the availability of safer alternatives.82
2. Support research and educational interventions in emergency departments to enhance safer opioid prescribing practices in this setting.83-86

If these evidence-based recommendations are enacted quickly, BC has the potential to dramatically reduce fatal overdoses, abuse, addiction and other severe harms related to unsafe opioid prescribing.

*Together, we can do this. The time for action is now.*

# Appendix A: Contributors and endorsers

|  |  |  |  |
| --- | --- | --- | --- |
| *1.* | Keith Ahamad, MD, CCFP, CISAM  Family and Addiction Medicine Physician, | *11.* | Rashmi Chadha, MBChB, MScCH, CCFP, ABAM |
|  | Providence Health Care / Vancouver Coastal Health  Research Scientist, B.C. Centre for Excellence in HIV/AIDS  Clinical Assistant Professor, Faculty of Medicine, |  | Addiction Medicine Physician, Vancouver Coastal  Health  Medical Consultant, College of Physicians and Surgeons of British Columbia |
|  | UBC | *12.* | Veronic Clair, MD, MSc, CCFP, FRCPC, PhD |
| *2.* | Sandra Allison, MPH, CCFP, FRCPC |  | Addiction Medicine Physician, Vancouver Coastal |
|  | Chief Medical Health Officer, Northern Health |  | Health |
|  | Adjunct Professor, School of Health Sciences, |  | Adjunct Professor, Faculty of Health Sciences, SFU |
|  | UNBC |  | Clinical Faculty, Faculty of Medicine, UBC |
|  | Clinical Assistant Professor, School of Population | *13.* | Trevor A. Corneil, MHSc, MD, FCFP, FRCPC |
| *3.* | and Public Health, UBC  Cecilia Benoit, PhD |  | Chief Medical Health Officer, Interior Health  Drug Overdose and Alert Partnership Committee |
|  | Fellow, Royal Society of Canada |  | Member |
|  | Fellow, Canadian Academy of Health Sciences |  | Clinical Professor, School of Population and Public |
|  | Scientist, Centre for Addictions Research of B.C. |  | Health, UBC |
|  | Professor, Department of Sociology, University of | *14.* | Cassandra Djurfors, MD, CCFP |
| *4.* | Victoria  Neal Berger |  | Medical Coordinator, Raven Song Primary Care,  Vancouver Coastal Health |
|  | Executive Director, Cedars at Cobble Hill | *15.* | Richard Dubras, MSc, MEd |
| *5.* | Addiction Treatment Centre  James I. Brooks, MD, FRCPC |  | Executive Director, Richmond Addiction Services  Society |
|  | Medical Director, Communicable Disease |  | British Columbia Association of Clinical |
|  | Prevention and Control Service |  | Counsellors |
|  | British Columbia Centre for Disease Control | *16.* | Nadia Fairbairn, MD, FRCPC |
| *6.* | Bill Bullock, MD, CCFP |  | Fellow, St. Paul’s Hospital Goldcorp Addiction |
|  | Family and Addiction Medicine Physician, Victoria |  | Medicine Fellowship |
|  | Community Detox | *17.* | Caroline Ferris, MD, CCFP, FCFP |
| *7.* | Susan Burgess, MD |  | Primary Care and Addiction Medicine Physician |
|  | Family and Communty Medicine Physician, |  | Clinical Assistant Professor, Faculty of Medicine, |
|  | Providence Health Care / Vancouver Coastal Health |  | UBC |
|  | Clinical Associate Professor, Faculty of Medicine, | *18.* | Michelle Fortin |
| *8.* | UBC  Mike Burns, MD, CCFP |  | Co-Chair, B.C. Alliance for Mental Health/Illness  and Problematic Substance Use |
|  | Family Physician, Providence Health Care |  | Executive Director, Watari Counselling & Support |
| *9.* | Jane A. Buxton, MBBS, MHSc, FRCPC |  | Services |
|  | Professor and Director MPH Practicum, School of | *19.* | Emilie Gladstone, MPH |
|  | Population and Public Health, UBC |  | Pharmaceutical Policy Researcher, Centre for |
| *10.* | David W. Byres, MSN, BA, RN, CHE |  | Health Services and Policy Research, Faculty of |
|  | Executive Vice President, Clinical Integration and |  | Medicine, UBC |

Renewal

Providence Health Care

Adjunct Professor, School of Nursing, UBC

1. Silvia Guillemi, MD

Assistant Director, J. Ruedy Immunodeficiency Clinic (IDC), St Paul’s Hospital

Director of Clinical Education, B.C. Centre for Excellence in HIV/AIDS

Clinical Associate Professor, Faculty of Medicine, UBC

1. David Hall, MD, CCFP

Medical Director for Primary Care, Vancouver Coastal Health

Medical Lead, Regional HIV Program, Vancouver Coastal Health

1. Scott Harrison, RN, BScN, MA, CCHNC Director Urban Health & HIV/AIDS, Providence Health Care

Adjunct Professor, School of Nursing, UBC

1. Kanna Hayashi, PhD

Research Scientist, Urban Health Research Initiative, B.C. Centre for Excellence in HIV/AIDS Assistant Professor, Faculty of Medicine, UBC

1. Ramm Hering, MSc, MD, CCFP, Dip PH Family and Addiction Medicine Physician, Pandora Clinic
2. Lorne Hildebrand

Executive Director, EDGEWOOD

1. Ronald Joe, MD

Associate Medical Director, Addiction Services, Vancouver Coastal Health

1. P.R.W. Kendall, B.C. Provincial Health Officer
2. Thomas Kerr, PhD

Director, Urban Health Research Initiative

B.C. Centre for Excellence in HIV/AIDS Professor, Faculty of Medicine, UBC

1. Piotr Klakowicz, MD, MPH, CCFP Family and Addiction Medicine Physician, Providence Health Care

Vancouver Native Health Society Medical Clinic

1. Erin Knight, MD, CFPC

Fellow, St. Paul’s Hospital Goldcorp Addiction Medicine Fellowship

1. Mel Krajden, MD, FRCPC

Medical Head, Hepatitis, B.C. Centre for Disease Control

Acting Medical Director, Public Health Laboratory,

B.C. Centre for Disease Control

1. Andrea Krüsi, PhD

Research Scientist, Gender and Sexual Health Initiative, B.C. Centre for Excellence in HIV/AIDS

1. Leslie Lappalainen, MD, CCFP

Family and Addiction Medicine Physician, Providence Health Care

Clinical Instructor, Faculty of Medicine, UBC

1. Julia MacIsaac, MD, MPH, FRCPC Family and Addiction Medicine Physician, Providence Health Care

Alliance Clinic, Surrey, B.C. LAIR Centre, Vancouver

1. Brandon Marshall, PhD

Assistant Professor, Department of Epidemiology, Brown University School of Public Health

1. Leslie McBain, Community Advocate

Moms United and Mandated to Saving the lives of Drug Users (MumsDU)

1. Rita McCracken, MD, CCFP

Associate Head, Providence Health Care Clinical Assistant Professor Faculty of Medicine, UBC

1. Garth McIver, MD

Medical Consultant, B.C. Methadone Program (CPSBC)

1. Mark McLean, MD, FRCPC

Addiction Medicine Physician, Providence Health Care / Vancouver Coastal Health

1. Ailve McNestry, MB, CCFP, CCBOM Deputy Registrar, Drug Programs College of Physicians & Surgeons of B.C.
2. M-J Milloy, PhD

Research Scientist, Urban Health Research Initiative, B.C. Centre for Excellence in HIV/AIDS Assistant Professor, Faculty of Medicine, UBC

1. Julio S.G. Montaner, OC, OBC, MD, DSc (hon), FRCPC, FCCP, FACP, FRSC

Professor and Head, UBC–Division of AIDS

UBC and St. Paul’s Hospital Foundation Chair in AIDS Research

Director, B.C. Centre for Excellence in HIV/AIDS, St. Paul’s Hospital, Providence Health Care

1. Steve Morgan, PhD

Professor, School of Population and Public Health, UBC

1. Lisa Muhler, PhD in Addictions Counselling

Registered Psychologist

Clinical Director, Top of the World Ranch Treatment Centre

1. Seonaid Nolan, MD, FRCPC, Dip ABAM Internal Medicine and Addiction Medicine Physician, Providence Health Care

Research Scientist, Urban Health Research Initiative, B.C. Centre for Excellence in HIV/AIDS Clinical Assistant Professor, Faculty of Medicine, UBC

1. Michael Norbury, MBChB, MSc, BSc (Hons), CCFP

Family and Addiction Medicine Physician,

Vancouver Coastal Health

1. Daniel Paré, MD, CCFP

Inner City Primary Care & Assertive Community Treatment Team, Vancouver Coastal Health Medical Coordinator, Downtown Community Health Centre

Clinical Instructor, Faculty of Medicine, UBC

1. Gerrard Prigmore, MB, BCh, MRCGP, DFSRH, CCFP, Dip ABAM

Family and Addiction Medicine Physician, Prince

George

1. Nitasha Puri, MD, CCFP, Dip ABAM

Family and Addiction Medicine Physician, Vancouver Coastal Health / Portland Hotel Medical Clinic / Fraser Health Authority

Clinical Instructor, Faculty of Medicine, UBC

1. Dan Reist, MTh

Knowledge Exchange Assistant Director

Centre for Addictions Research of B.C., University of Victoria

1. Lindsey Richardson, DPhil

Research Scientist, Urban Health Research Initiative, B.C. Centre for Excellence in HIV/AIDS Assistant Professor, Department of Sociology, UBC

1. Launette Rieb, MSc, MD

Family and Addiction Medicine Physician Clinical Associate Professor, Faculty of Medicine, UBC

1. Kimberly Rutherford, MD, MSc, CCFP Medical Coordinator, Primary Outreach Services, Vancouver Coastal Health

Medical Staff, St. Paul’s Hospital, Providence Health Care

Clinical Instructor, Faculty of Medicine, UBC

1. Andrea Ryan, BSc, MD, CCFP

Family and Addiction Medicine Physician, Providence Health Care

Vancouver Detox Physician, Vancouver Coastal Health

1. Mark Sadler, MC

Addiction Counsellor

Executive Director, Top of the World Ranch Treatment Centre

1. Todd Sakakibara, MD, CCFP, FCFP, Dip ABAM

Family and Addiction Medicine Physician,

Vancouver Coastal Health

Clinical Associate Professor, Faculty of Medicine, UBC

1. Kate Shannon, MPH, PhD

Director, Gender and Sexual Health Initiative

B.C. Centre for Excellence in HIV/AIDS Associate Professor of Medicine, Faculty of Medicine, UBC

Associate Faculty, School of Population and Public Health, UBC

1. David H. Smith, MD, Dip ABAM Okanagan Psychiatric Services, Interior Health Clinical Instructor, Faculty of Psychiatry, UBC
2. Marshall K. Smith

Director of Corporate Development and Community Relations

Cedars at Cobble Hill Addiction Treatment Centre

1. Kate Smolina, PhD

Banting Postdoctoral Fellow. Centre for Health Services and Policy Research

School of Population and Public Health, UBC

1. M. Eugenia Socías, MD

Researcher, B.C. Centre for Excellence in HIV/ AIDS

Postdoctoral Fellow, Department of Medicine, UBC

1. Tim Stockwell, PhD

Director, Centre for Addictions Research of B.C. Professor, Department of Psychology, University of Victoria

1. Lorinda Strang

Executive Director, Orchard Recovery Center

1. Christy Sutherland, MD, CCFP, Dip ABAM Medical Director, Portland Hotel Society Community Services Society

Family and Addiction Medicine Physician, Providence Health Care

Clinical Assistant Professor, Faculty of Medicine, UBC

1. Lianping Ti, PhD

Researcher, B.C. Centre for Excellence in HIV/ AIDS

Postdoctoral Fellow, Faculty of Medicine, UBC

1. David Tu, MD, CCFP

Family and Addiction Medicine Physician, Vancouver Native Health Society

Clinical Associate Professor, Faculty of Medicine, UBC

1. Devin Tucker, MD

Addiction and Family Medicine Physician, Vancouver Coastal Health

1. Mark Tyndall, MD, ScD, FRCPC Executive Medical Director, B.C. Centre for Disease Control

Deputy Provincial Health Officer, Province of British Columbia

Director, UBC–BCCDC Research Institute Professor, School of Population and Public Health, UBC

1. Karen Urbanoski, PhD

Canada Research Chair in Substance Use, Addictions and Health Services

Scientist, Centre for Addictions Research of B.C. Assistant Professor, University of Victoria

1. Sharon Vipler, MD

Family and Addiction Medicine Physician, Providence Health Care

1. Dan Werb, PhD

Director, International Centre for Science in Drug Policy

1. Evan Wood, MD, PhD, ABIM, FRCPC

Professor of Medicine, Canada Research Chair in Inner City Medicine, UBC

Medical Director, Community Addiction Services, Vancouver Coastal Health / Providence Health Care

1. Steven Yau, MD, CCFP

Primary Care Physician, Downtown Community Health Centre, Strathcona Mental Health Team and Assertive Community Treatment Team, Vancouver Coastal Health

Clinical Assistant Professor, Faculty of Medicine, UBC

Medical Director, IMG Programming, Division of Continuing Professional Development, Faculty of Medicine, UBC

# Acknowledgments

We wish to acknowledge Pauline Voon (PhD candidate) for research and writing assistance in preparing this document. We also wish to thank James Nakagawa, Cheyenne Johnson, Carmen Rock, Lianlian Ti, Elaine Fernandes, Diane Pépin, Jehnifer Benoit, and Deborah Graham for their editorial and administrative assistance.

# References

1. International Narcotics Control Board. Narcotic drugs: Estimated world requirements for 2012, statistics for 2010. Vienna, Austria: International Narcotics Control Board, 2011.
2. Shield KD, Jones W, Rehm J, Fischer B. Use and nonmedical use of prescription opioid analgesics in the general population of Canada and correlations with dispensing levels in 2009. Pain Res Manag 2013;18:69-74.
3. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician 2012;15:ES191-203.
4. Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Res Manag 2011;16:445-50.
5. Fischer B, Jones W, Krahn M, Rehm J. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf 2011;20:1269-77.
6. Fischer B, Jones W, Rehm J. Trends and changes in prescription opioid analgesic dispensing in Canada 2005- 2012: an update with a focus on recent interventions. BMC Health Serv Res 2014;14:90.
7. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med 2011;5:e13-22.
8. Smolina K, Gladstone EJ, Morgan SG. Pharmaceutical opioid monitoring and surveillance in British Columbia: Current state and future direction: University of British Columbia; 2015.
9. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015;162:276-86.
10. Franklin GM, American Academy of N. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology 2014;83:1277-84.
11. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine (Phila Pa 1976) 2014;39:556-63.
12. Nosyk B, Fischer B, Sun H, Marsh DC, Kerr T, Rehm JT, Anis AH. High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: results from a population-level retrospective cohort study. Am J Addict 2014;23:257-64.
13. Gladstone EJ, Smolina K, Morgan SG. Trends and sex differences in prescription opioid deaths in British Columbia, Canada. Inj Prev 2015.
14. Cunningham CM, Hanley GE, Morgan S. Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use. Health Policy 2010;97:122-9.
15. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug

overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 2015;350:h2698.

1. Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction 1996;91:405-11.
2. Perret G, Deglon JJ, Kreek MJ, Ho A, La Harpe R. Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. Addiction 2000;95:1647-53.
3. Leece P, Cavacuiti C, Macdonald EM, Gomes T, Kahan M, Srivastava A, Steele L, Luo J, Mamdani MM, Juurlink DN, Canadian Drug S, Effectiveness Research N. Predictors of Opioid-Related Death During Methadone Therapy. J Subst Abuse Treat 2015;57:30-5.
4. BC Ministry of Health. Treating Opioid Overdose: B.C.’s Take Home Naloxone Program. HealthLinkBC Files Number 118, March 2015.
5. Government of British Columbia. Fatal Victims of Crashes Involving Alcohol and/or Drug. Burnaby (BC): Research and Data Unit, Policy and Strategic Initiatives Branch, RoadSafetyBC, BC Ministry of Justice; October 2014.
6. Coroners Service of British Columbia. Opiate Deaths.

Burnaby: BC Ministry of Justice; May 2013.

1. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S, 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW, American Society of Interventional Pain

P. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment. Pain Physician 2012;15:S1-65.

1. Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. Pharmacoepidemiol Drug Saf 2013;22:438-42.
2. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011;305:1315-21.
3. Gomes T, Redelmeier DA, Juurlink DN, Dhalla IA, Camacho X, Mamdani MM. Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med 2013;173:196-201.
4. Braden JB, Russo J, Fan MY, Edlund MJ, Martin BC, DeVries A, Sullivan MD. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med 2010;170:1425-32.
5. Wisniewski AM, Purdy CH, Blondell RD. The epidemiologic association between opioid prescribing, non-

medical use, and emergency department visits. J Addict Dis 2008;27:1-11.

1. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011;305:1346-7.
2. Turner SD, Gomes T, Camacho X, Yao Z, Guttmann A, Mamdani MM, Juurlink DN, Dhalla IA. Neonatal opioid withdrawal and antenatal opioid prescribing. CMAJ Open 2015;3:E55-61.
3. US National Institute on Drug Abuse (NIDA). Abuse of Prescription Pain Medications Risks Heroin Use. January 2014: <http://www.drugabuse.gov/related-topics/> trends-statistics/infographics/abuse-prescription-pain- medications-risks-heroin-use.
4. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone

D. “Every ‘never’ I ever said came true”: transitions from opioid pills to heroin injecting. Int J Drug Policy 2014;25:257-66.

1. Firestone M, Fischer B. A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: behaviours, preferences and drug availability. Harm Reduct J 2008;5:30.
2. Frank D, Mateu-Gelabert P, Guarino H, Bennett A, Wendel T, Jessell L, Teper A. High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. Int J Drug Policy 2015;26:84-91.
3. Mateu-Gelabert P, Guarino H, Jessell L, Teper A. Injection and sexual HIV/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City. J Subst Abuse Treat 2015;48:13-20.
4. Guarino H, Marsch LA, Deren S, Straussner SL, Teper A. Opioid Use Trajectories, Injection Drug Use, and Hepatitis C Virus Risk Among Young Adult Immigrants from the Former Soviet Union Living in New York City. J Addict Dis 2015;34:162-77.
5. Young AM, Havens JR. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction 2012;107:587-96.
6. Weeks C. Solving the painkiller crisis: It’s in the hands of doctors Globe and Mail October 3, 2014.
7. The Canadian Press. Continuing education for opioid prescribing should be mandatory: CMA. August 24, 2015.
8. Kirkey S. ‘Weak’ doctors blamed for flood of prescription painkillers behind epidemic of drug-related deaths. National Post August 24, 2015.
9. Gomes T, Mamdani MM, Paterson JM, Dhalla IA, Juurlink DN. Trends in high-dose opioid prescribing in Canada. Can Fam Physician 2014;60:826-32.
10. Dhillon S. RCMP announce charges in fentanyl bust in Burnaby. Globe and Mail 2015 September 3, 2015.
11. Burgmann T. RCMP deals with China, UN as fentanyl deaths surge in Canada. Toronto Sun August 12, 2015.
12. Wood G. RCMP seize fentanyl-laced drugs. Richmond News August 19, 2015.
13. Canadian Centre on Substance Abuse (CCSA) and Canadian Community Epidemiology Network on Drug

Use (CCENDU). CCENDU Bulletin: Deaths Involving Fentanyl in Canada, 2009-2014. August 2015. [http://www.](http://www/) ccsa.ca/Resource Library/CCSA-CCENDU-Fentanyl- Deaths-Canada-Bulletin-2015-en.pdf.

1. McKee G, Amlani A, Buxton J. Illicit fentanyl: An emerging threat to people who use drugs in BC. BC Medical Journal 2015;57:235.
2. Crawford T. Coroner confirms fentanyl linked to deaths of young North Vancouver couple. Vancouver Sun July 31, 2015.
3. McElroy J. Family of Burnaby teen dead of suspected fentanyl overdose speaks out. Global News August 3, 2015.
4. Mulholland A. Fentanyl, the painkiller officials warn is taking lives. CTV News August 4, 2015.
5. Dhillon S. Increase in fentanyl-related deaths prompt calls for ‘antidote’. The Globe and Mail August 14, 2015.
6. Vancouver Police Department. Media Release: Police warn drug users following spike in overdoses. August 9, 2015.
7. Wintonyk D. Fentanyl suspected for 16 Vancouver overdoses in 1 day. CTV News August 10, 2015.
8. Quan D. ‘A witch’s brew’: Authorities boost warnings over illicit street drug fentanyl after rash of deaths. National Post August 11, 2015.
9. Vancouver Police Department. Media Release: Police Focus on Deadly Fentanyl Drug Trade. March 3, 2015.
10. Werb D, Rowell G, Guyatt G, Kerr T, Montaner J, Wood E. Effect of drug law enforcement on drug market violence: a systematic review. Int J Drug Policy 2011;22:87-94.
11. Global Commission on Drug Policy. The War on Drugs and HIV/AIDS: How the Criminalization of Drug Use Fuels the Global Pandemic. Report of the Global Commission on Drug Policy; June 2012.
12. Lader M. Benzodiazepines revisited—will we ever learn?

Addiction 2011;106:2086-109.

1. Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012;125:8-18.
2. Howard P, Twycross R, Shuster J, Mihalyo M, Wilcock A. Benzodiazepines. J Pain Symptom Manage 2014;47:955-64.
3. Ickowicz S, Hayashi K, Dong H, Milloy MJ, Kerr T, Montaner JS, Wood E. Benzodiazepine use as an independent risk factor for HIV infection in a Canadian setting. Drug Alcohol Depend 2015.
4. Government of British Columbia. PharmaCare Policy Manual 2012. Section 2.3: What is PharmaNet? (2012). [http://www2.gov.bc.ca.](http://www2.gov.bc.ca/)
5. Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN, Canadian Drug S, Effectiveness Research N. Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. CMAJ 2012;184:E852-6.
6. Allen MJ, Asbridge MM, Macdougall PC, Furlan AD, Tugalev O. Self-reported practices in opioid management of chronic noncancer pain: a survey of Canadian family physicians. Pain Res Manag 2013;18:177-84.
7. Culter K., President and CEO, Medinet Vancouver.

Personal communication, September 16, 2015.

1. Clancy N. Impostor seeking oxycodone lands B.C. doctors and pharmacists in trouble. CBC News June 23, 2015.
2. College of Physicians and Surgeons of BC. Drugs Requiring the Use of a Duplicate Prescription. [https://ww](http://www.cpsbc.ca/)w[.cpsbc.ca/](http://www.cpsbc.ca/) programs/prp/drugs-duplicate-prescription.
3. College of Physicians and Surgeons of Alberta. Notice to prescribers: Benzodiazepines added to Alberta drug monitoring list. July 2015. <http://www.cpsa.ab.ca/Services/> Triplicate\_Prescription\_Program/TPP\_Overview.aspx.
4. Simoni-Wastila L, Ross-Degnan D, Mah C, Gao X, Brown J, Cosler LE, Fanning T, Gallagher P, Salzman C, Soumerai SB. A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in medicaid patients with chronic psychiatric and neurologic disorders. Clin Ther 2004;26:322-36.
5. Hohl CM, Abu-Laban RB, Zed PJ, Brubacher JR, Tsai G, Kretz P, Nemethy K, Purssell RA. Patient-reported adverse drug-related events from emergency department discharge prescriptions. CJEM 2010;12:331-8.
6. Watt-Watson J, McGillion M, Hunter J, Choiniere M, Clark AJ, Dewar A, Johnston C, Lynch M, Morley-Forster P, Moulin D, Thie N, von Baeyer CL, Webber K. A survey of prelicensure pain curricula in health science faculties in Canadian universities. Pain Res Manag 2009;14:439-44.
7. Wenghofer EF, Wilson L, Kahan M, Sheehan C, Srivastava A, Rubin A, Brathwaite J. Survey of Ontario primary care physicians’ experiences with opioid prescribing. Can Fam Physician 2011;57:324-32.
8. The National Center on Addiction and Substance Abuse (CASA) at Columbia University. Missed Opportunity: National Survey of Primary Care Physicians and Patients on Substance Abuse. Chicago: Survey Research Laboratory, University of Illinois; April 2000: http://www.casacolumbia. org.
9. The National Center on Addiction and Substance Abuse (CASA) at Columbia University. Addiction Medicine: Closing the Gap between Science and Practice. New York: CASA Columbia; June 2012: [http://www.casacolumbia.org.](http://www.casacolumbia.org/)
10. Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. Primary Care Physicians’ Knowledge And Attitudes Regarding Prescription Opioid Abuse and Diversion. Clin J Pain 2015.
11. Maremmani I, Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict 2010;19:557-68.
12. Marteau D, McDonald R, Patel K. The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. BMJ Open 2015;5:e007629.
13. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009;104:73-7.
14. Luty J, O’Gara C, Sessay M. Is methadone too dangerous for opiate addiction? BMJ 2005;331:1352-3.
15. Substance Abuse and Mental Health Ser vices Administration (SAMHSA), US Department of Health and Human Services. Opioid drugs in maintenance and detoxification treatment of opiate addiction. Final rule. Federal Register 2001;66(11):4076-102.
16. BC Harm Reduction Strategies and Services. Toward the Heart: A project of the provincial Harm Reduction Program. Naloxone: Preventing overdoses, saving lives. [http://towardtheheart.com/naloxone/.](http://towardtheheart.com/naloxone/)
17. Beletsky L, Rich JD, Walley AY. Prevention of fatal opioid overdose. JAMA 2012;308:1863-4.
18. Wood E, Samet JH, Volkow ND. Physician education in addiction medicine. JAMA 2013;310:1673-4.
19. Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A, National Opioid Use Guideline G. Canadian guideline for safe and effective use of opioids for chronic noncancer pain. Appendix B-6: Benzodiazepine Tapering. Can Fam Physician 2011;57:1269-76, e419-28.
20. Gugelmann H, Shofer FS, Meisel ZF, Perrone J. Multidisciplinary intervention decreases the use of opioid medication discharge packs from 2 urban EDs. Am J Emerg Med 2013;31:1343-8.
21. Del Portal DA, Healy ME, Satz WA, McNamara RM. Impact of an Opioid Prescribing Guideline in the Acute Care Setting. J Emerg Med 2015.
22. Kilaru AS, Gadsden SM, Perrone J, Paciotti B, Barg FK, Meisel ZF. How do physicians adopt and apply opioid prescription guidelines in the emergency department? A qualitative study. Ann Emerg Med 2014;64:482-9 e1.
23. Kunins HV, Farley TA, Dowell D. Guidelines for opioid prescription: why emergency physicians need support. Ann Intern Med 2013;158:841-2.